Roth MKM keeps a Buy rating and $20 price target on OptimizeRx after the company provided Q4 outlook for adjusted EBITDA at $5.8M, up from $3.9M last year, as part of its 8-K disclosure last week. While more detailed data such as gross margins, ARPU, retention, operating expenses, and most balance sheet metrics are missing, the results are supportive of a move higher in 2024, and the firm expects record top and bottom-line results to continue, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx initiated with an Outperform at JMP Securities
- OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET
- OptimizeRx cuts FY24 revenue view to at least $100M from at least $110M
- OptimizeRx backs FY23 revenue view at least $68M-$70M, consensus $69.85M
- OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023
